Several neuroimaging studies of patients with OCD have pointed to basal ganglia and the frontal cortical regions being relevant for an understanding of the pathophysiology and therapy of OCD. In a search for the neural substrate underlying the therapeutic action of paroxetine in the therapy of OCD we measured regional glucose metabolism in a PET study of 20 OCD patients before and after at least 3 months of treatment. We used 18-fluoro-deoxyglucose PET-scanning to measure regional cerebral glucose metabolic rate (rCMRglc) in 20 non-depressed patients fulfilling DSM-IV criteria for OCD. Patients were studied before and after 12-20 wk of treatment with the serotonin re-uptake inhibitor paroxetine. Clinical assessment rating with the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) was performed before the first and after the second study. The PET data was analysed regionally using statistical parametric mapping (SPM-96). A clinical improvement was indicated by a mean decrease of 55 % in the Y-BOCS score. There was no difference in global cerebral metabolism before and after treatment whereas a post-treatment reduction in normalized rCMRglc was found in the right caudate nucleus. This finding also showed a significant positive correlation with symptom severity. Our results support hypotheses regarding a malfunction of the cortico-striato-thalamic system in the pathophysiology of OCD and particularly point to the caudate nucleus playing an important role for the therapeutic action of paroxetine in the treatment of OCD.
Introduction
Obsessive-compulsive disorder (OCD) is a common psychiatric disorder which in several studies has been shown to affect more than 1 % of the population (Rasmussen and Eisen, 1994) . The hallmark symptoms of OCD are recurrent intrusive thoughts (obsessions) and repetitive ritualistic behaviour (compulsions). Accumulating evidence suggests an association with dysfunction in specific brain regions. Convergent data including ethological and experimental observations (Kolb, 1997 ; Rapoport, 1991) , clinicopathological findings (Cummings and Cunningham, 1992 ; Swedo et al., 1989) , magnetic resonance imaging (MRI) (Robinson et al., 1995) , positron emission tomography (PET) (Baxter et al., 1988 (Baxter et al., , 1992  Correspondence : Dr T. G. Bolwig, Department of Psychiatry, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark. Tel.: j45 35 45 62 33 Fax : j 45 35 26 04 13 E-mail : bolwigtg!rh.dk Benkelfat et al., 1990 ; Perani et al., 1995 ; Rauch et al., 1994 ; Schwartz et al., 1996 ; Swedo et al., 1992) and functional MRI (Breiter et al., 1996 ; McGuire et al., 1994) have implicated the basal ganglia along with the related cortical and thalamic structures in the pathophysiology of OCD. The well-documented effect of both clomipramine and selective serotonin reuptake inhibitors (SSRIs) in the therapy of OCD further points to a biological origin of the disorder (Baxter et al., 1992 ; Insel, 1992 ; Rapoport and Wise, 1988) .
Previous imaging studies of the effects of treatment have been conducted with either clomipramine, SSRIs or behaviour therapy (Baxter et al., 1992 ; Benkelfat et al., 1990 ; Saxena et al., 1999 ; Schwartz et al., 1996) . We chose to use paroxetine in the present study based on our positive clinical experience with this drug and because paroxetine has a well-known higher affinity for the serotonin transporter than the other SSRIs in clinical use. The aim of the present investigation was therefore to test if paroxetine which is widely used in the therapy of OCD exerts an effect in striatal regions and related subcortical and cortical structures similar to the one that has been described. Data from the present study was presented in a preliminary form at the 4th International Conference on Mapping of the Human Brain, Montreal, 1998 (Hansen et al., 1998) .
Methods

Subjects and procedures
Twenty outpatients (12 men, 8 women), with a mean age of 33 yr (.. l 10n0 yr) (range 19-57 yr) fulfilling the DMS-III-R criteria for OCD were recruited from the Copenhagen University Hospital OCD Study Programme. The diagnoses and clinical evaluation were made on the basis of structured interviews designed for the study programme by two of the authors (E.S.H. and T.G.B.), both trained psychiatrists. Before entering the study the patients were interviewed with BPRS (Brief Psychiatric Rating Scale), the 17-item Hamilton Depression Scale (HAMD) and the Hamilton Anxiety Scale (HAS) to rule out severe symptoms that might interfere with the DSM-III-R criteria for OCD. OCD symptoms were assessed using the Yale-Brown ObsessiveCompulsive Scale (Y-BOCS) (Goodman et al., 1989) . Twenty-four patients entered the study. Four did not complete ; two, because of discomfort (claustrophobic experience) during the first PET scan, one due to drug discontinuation. As no patient showed clinical signs of drug or alcohol influence, blood sampling was omitted. One patient, previously healthy, a heavy cigarette smoker, died of acute myocardial infarction before completing the study.
All patients were physically healthy and drug-free for 3 wk prior to the study. They had no previous history of neurological illness, including Tourette's syndrome and other tic disorders. Two patients were left-handed, and 18 right-handed.
The duration of OCD symptomatology ranged from 5 to 30 yr, with a mean of 18 yr (.. l 7n7 yr). All patients had obsessions as well as compulsions of varying severity. Nine patients had checking behaviour as a predominant symptom, three washing rituals, five patients had mixed symptomatology with repetition rituals, counting and need for symmetry and exactness. In two patients the obsessions were clearly predominant, while one patient (no. 17) was highly compulsive with only discrete obsessions. (For details see Table 1 .)
In 11 of the patients there was co-morbidity with other conditions. Based on a structured interview we found that 8 patients had suffered symptoms of major depression, 2 had had specific phobia and 1 panic disorder. However, The caudate nucleus in OCD none of these co-morbid conditions had become manifest for at least 6 months prior to the study.
Twelve patients had a family history of affective disorder, OCD and other anxiety disorders and substance\ alcohol abuse among first-degree relatives. In 8 patients there was no known family history of psychopathology.
In 15 patients previous psychotherapeutic or pharmacological attempts to treat OCD symptoms had been made, either by a psychiatrist, general practitioner or psychologist. Subjects were rated with Y-BOCS at the time of the PET scan before and after treatment. Responders to treatment were those who rated as either ' much improved ' or ' very much improved ' on item 18 of the Y-BOCS at the time of the second PET scan. Nonresponders were such who scored ' no change ' or ' minimally improved ' on the same item.
Control subjects were recruited from advertisements. They consisted of 11 healthy volunteers, 3 females, 8 males with a mean age of 32 yr (.. l 6n0 yr) (range 20-59 yr). Nine subjects were right-handed, 1 was lefthanded, and 1 was ambidextrous. Based on a structured interview, none of the control subjects had past or present neurological or psychiatric disorders or active use of medication or recreational drugs. Written informed consent was obtained from patients and controls according to the Declaration of Helsinki II, and the study was approved by the local Ethics Committee of Copenhagen University Hospital [ J. Nr. (KF) 02-176\94].
Treatment
The treatment with paroxetine was started with 20 mg\d with an increase of doses to 40-80 mg\d, the maximal dose in most patients was reached after 6 wk of treatment. The mean maximal dose was 60 mg\d (range 40-80 mg\d). No monitoring of plasma levels was made. Adherence to the treatment regimen was indicated by the fact that almost all of the patients were complaining of the well-known side-effects of paroxetine, i.e. initial nausea, profuse sweating, shortened sleep duration and sexual dysfunction. During the first 2 wk of treatment 3 patients were allowed to take 15 mg\d oxazepam with gradual tapering off over 2 wk.
The patients had at least one consultation every 4 wk during the study. They were encouraged to combat symptoms, but otherwise were not given any formal psychotherapy. They were not allowed to and did not receive psychotherapy from outside of the study.
PET scanning
Regional cerebral glucose metabolic rate (rCMRglc) was measured using 18-fluoro-deoxyglucose (FDG) PET scanning. The first study was made the day after clinical evaluation, the second, with the patients in paroxetine treatment, 12-20 wk later.
PET scans were obtained with an 18-ring GE-Advance scanner (General Electric Medical Systems, Milwaukee, WI, USA) operating in 3D acquisition mode (total axial field of view, 15n2 cm ; in-plane resolution, 5 mm) (Lewellen et al., 1996) . A transmission scan was performed for attenuation correction.
In local analgesia, catheters were placed in an antecubital vein and in the radial artery of the non-dominant arm. Resting in the supine position with eyes covered and noise level kept to a minimum, each subject received an intravenous bolus injection of approx. 200 MBq 18-FDG. The arterial FDG input function was determined from small arterial blood samples with increasing time-interval to the end of the scan period. After 1n5 h the subject was placed in the scanner, and a 20 min 3D scan was obtained 2 h after tracer injection in order to minimize errors in CMRglc induced by the use of standard rate constants (Huang et al., 1980) . Quantitative cerebral glucose metabolism was calculated using the autoradiographic method with the use of standard rate constants (k1* l 0n102, k2* l 0n130, k3* l 0n062, k4* l 0n0068). A fixed value of 0n55 was used for the lumped constant.
Data analyses
For all patients and control subjects the complete brain volume was sampled. Image analysis was performed using standard methods. The PET images were aligned (AIR 2n0) (Woods et al., 1992) , transformed into the Montreal Neurological Institute (MNI) version of the atlas of Talairach and Tournoux (1988) (Frackowiak and Friston, 1994) and filtered by a 16 mm isotropic gaussian filter using Statistical Parametric Mapping software (SPM-96, Wellcome Department of Cognitive Neurology, London, UK) (Friston et al., 1995) . The global CMRglc was measured by the application on the stereotactically normalised images of an identical Region of Interest (ROI) for all subjects covering the whole brain excluding ventricles in all slices. Significant changes in the rCMRglc were assessed with and without removal of the global CMRglc as a confounder. When so done, this was accomplished by proportional normalization of global brain glucose metabolism to a value of 25 µmol\100 g;min using the procedure inherent in SPM-96. Testing the null hypothesis rejecting regionally specific effects was performed comparing conditions or groups on a voxel-by-voxel basis. The same three analyses of regional effects were performed on both the quantitative and the normalized PET images. These consisted of an unpaired comparison between healthy controls and An illustration of the normalized lCMRglu in the right caudate nucleus. The data were sampled from the SPM analysis at the co-ordinate of maximal decrease as a result of treatment in the OCD patients, x, y, z l 10, 12, k2, and subsequently sampled from the control subjects at the same location. The raw data values and their means in each group\condition are shown. The decrease the OCD group following treatment (4n2 %) was significant at the p 0n05 level after correction for multiple independent comparisons. There was no significant difference between controls and OCD patients before treatment (p l 0n39, Mann-Whitney U test).
OCD patients before pharmacological treatment at a point when symptoms were most severe ; a paired comparison within the OCD group to localize possible regional effects of pharmacological treatment on the OCD patients ; and finally a parametric analysis of OCD patients correlating the rCMRglc to the Y-BOCS score as a measure of symptom severity. This last analysis was performed by defining all Y-BOCS scores (n l 40), both before and after treatment, as a covariate of interest within the SPM-96 general linear model and resembles the strategy used by McGuire et al. (1994) . All comparisons were performed as two one-tailed tests following the SPM-96 convention. The resulting set of voxel values constituted a statistical parametric map of the t statistic, SPM(t). By transforming values from the SPM(t) into the unit gaussian distribution using a probability integral transform changes could be reported in Z scores [SPM(Z)]. Voxels were considered significant if their Z score exceeded a threshold of p 0n05 (Z 4n27) after correction for multiple nonindependent comparisons as described by Friston (1994) , Friston et al. (1995) and Poline et al. (1997) . The number of effective comparisons,  or resolution elements, was 260 in our study. The resulting significant foci were characterized in terms of the number of voxels and peak Z score above the corrected threshold level. The threshold was subsequently dropped to Z 1n64 (or p 0n05 uncorrected) in order to observe activation tendencies.
Statistical analysis
In the unpaired comparisons between global rCMRglc values between control group and OCD patients before The caudate nucleus in OCD treatment a non-parametic Mann-Whitney U test was used at p 0n05. The Y-BOCS scores and global rCMRglc values before and after medical treatment were analysed using the Wilcoxon paired sign test for nonparametric data. Spearman's rank correlation was used to test for a correlation between the change in Y-BOCS score and the change in rCMRglc in the right caudate nucleus at a significance threshold of p 0n05. This was performed both for the change in absolute values and for the change in percent of the values before treatment.
Results
Clinical results
The 20 patients entering the study had the following mean scores : BPRS : 2n3 (.. 1n9), HAMD : 6n4 (.. 3n4), HAS: 30 (.. 3n0), Y-BOCS : 29n4 (.. 13n3). Following treatment the mean Y-BOCS score dropped by 55 % to 13n4 (.. 7n8), a highly significant result (p 0n001, The co-ordinates are given in the standard stereotactic space (19) as defined by the Montreal Neurological Institute (MNI). The change after treatment in absolute values and in percent of before treatment, Z score at the peak decrease, and the corresponding corrected p value using SPM-96, are quoted. Figure 1 ). Two patients were non-responders with a posttreatment score above 25 ; two patients were ' somewhat improved ' with a score between 20 and 25 while the remainder were either ' much improved ' or ' very much improved ' on item 18 of the Y-BOCS at the time of the second scan, with scores below 15.
PET scan results
The mean global CMRglc in µmol\100 g;min for the OCD patients was 21n6 (.. 2n8) before treatment and 20n8 (.. 2n8) after treatment. The difference was not significant, neither was the difference in the CMRglc between OCD patients before treatment and healthy controls who had a mean value of [19n7 (.. 3n2) µmol\100 g;min]. There were no significant differences found in any of the SPM analyses performed on the quantitative values of regional glucose metabolism (for right caudate nucleus see Figures 2, 3) . However, the analysis of the treatment effects on normalized rCMRglc of the OCD patients and the analysis correlating symptom severity to rCMRglc the same group of patients revealed essentially the same pattern of regional change. A significant decrease after treatment was found in the right caudate nucleus, which also showed a significant positive correlation with symptom severity at almost identical stereotactic co-ordinates (Tables 2, 3 ; Figures 2, 3) . The size of change in Y-BOCS score from pre-to posttreatment did not give a significant correlation with the amount of change in the rCMRglc in the right caudate nucleus, neither when calculated in absolute values (r s l 0n30, p l 0n18), nor when calculated in per cent of the pretreatment values (r s l 0n36, p l 0n11).
Reducing the level of significance (i.e. not correcting for multiple comparisons), the SPM analysis revealed several additional areas with a decreasing trend following treatment : the left inferior frontal cortex close to Broca's area, the right dorsolateral prefrontal cortex (DLPFC), the left anterior cingulate cortex, the right insula, the right inferior cuneus, and the left cerebellum (Table 2, Figure 5 ). Further, in these regions, we observed the same positive correlation between rCMRglc and Y-BOCS scores, although the correlation was signficant only in the right caudate nucleus (Table 3 ; Figures 1, 3) .
Discussion
In the present study of 20 OCD patients we evaluated the clinical and cerebral CMRglc changes following treatment with paroxetine. Due to conflicting findings in similar studies using either PET (Martinot et al., 1990) or SPECT (Lucey et al., 1997) in OCD patients, some of whom were also depressed, we studied patients with no co-morbid depression at the time of the study. We attempted to concentrate on the pharmacological side of the treatment by avoiding as much as possible a psychotherapeutic interference in the course of treatment although a certain placebo effect cannot be ruled out. We analysed the complete brain volume for significant changes in rCMRglc between patients and controls, and between pre-and post-treatment scans in OCD patients. Thus, no a priori hypotheses regarding the involvement of specific regions were applied in contrast to some previous studies, for example Baxter et al. (1992) , Saxena et al. (1999) . The clinical response to paroxetine treatment was high and induced a significant decrease in rCMRglc in the right caudate nucleus, a change which also had a positive correlation with symptom severity at almost identical stereotaxic co-ordinates (Tables 2, 3 ; Figures 2, 3) . Although the decrease of the right caudate nucleus stretched into the posterior parts of the right orbitofrontal region this did not include the region to the extent seen in previous studies (Swedo et al., 1992) . In the feedback loop between thalamus and the orbito-frontal cortex the caudate nucleus and globus pallidus are assumed to have a important regulatory role and the transfer of impulses from the caudate nucleus to globus pallidus exerts an inhibitory function via serotonin (Insel, 1992) . These regions seem to be crucial for the behavioural control lost in OCD patients, and down-regulation of caudate ' hyperactivity ' is thought to be implicated in the response to treatment with both SSRI and behavioural therapy (Baxter et al., 1992 ; Schwartz et al., 1996) . A similar asymmetry in the caudate nucleus rCMRglc response has previously been shown not only in response to treatment with fluoxetine and behaviour therapy (Baxter et al., 1992 ; Schwartz et al., 1996) , but also in symptom provocation studies (Breiter et al., 1996 ; McGuire et al., 1994 ; Rauch et al., 1994) . Thus, our data adds to an accumulating, and as yet unexplained, laterality of OCD pathophysiology. We were unable to demonstrate a pretreatment hyperactivity in either absolute or relative terms of the caudate nucleus glucose metabolism. Given the ample evidence for an increased metabolic activity in the caudate nucleus found in untreated OCD patients in other studies (Baxter et al., 1992 ; Benkelfat et al., 1990) , we suggest that the caudate metabolism in the present study was most likely normalized from a pretreatment, yet not by PET demonstrated, hyperactive state. Experimental variation did not, however, allow us to verify such a difference between OCD patients and controls.
It remains unsettled as to what extent the reduction in rCMRglc following paroxetine treatment was an unspecific effect of paroxetine itself. For ethical reasons we could not give the controls paroxetine to evaluate this effect. Alternatively, comparisons might have been made between groups of non-responding and responding OCD patients, but the high response rate to treatment would have required a very large number of patients enrolled into the study in order to make such a comparison. Similar findings in symptom provocation studies and behaviour therapy studies (Baxter et al., 1992 ; Breiter et al., 1996 ; McGuire et al., 1994 ; Schwartz et al., 1996) do, however, point to a significant involvement of the caudate nucleus and not just an unspecific change induced by drug treatment.
Using SPM to seek out trends in rCMRglc changes, we found reductions in regions, which in previous studies have been shown hyperactive or activated during symptom provocation in other PET studies (Baxter et al., 1992 ; Breiter et al., 1996 ; McGuire et al., 1994) . MRI studies showing individually highly variable regional structural differences in the brains of OCD subjects may explain why SPM sometimes gives different results across studies. Similar to our finding a weak activation was found in the right insula in a single study (Breiter et al., 1999) . Because of its tight functional and anatomical association with other paralimbic structures, the insula has been suggested to be involved in the processing of aversive stimuli that triggers OCD symptoms (Zald and Kim, 1996) . Recently, Phillips et al. (1997) demonstrated a significant activation of this region when normal controls perceived the facial expression of disgust, and our data may support the hypothesized involvement of this region in the generation of OCD symptoms.
The right caudate nucleus also gave robust correlations of rCMRglc with symptom severity obtained with both SPM.
In conclusion, we find the metabolic changes induced in particular brain regions of OCD patients as a result of successful treatment with the SSRI paroxetine to be in accordance with the majority of imaging studies in which the tricyclic antidepressant clomipramine, the SSRI fluoxetine, and behaviour therapy have been applied. Using the SPM approach in the present study we add to the accumulation of evidence pointing to specific brain regions, in particular the right caudate nucleus being involved in the pathophysiology of OCD.
